Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Dividends payables Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Non-Current Assets Non-Current Debt Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

TherapeuticsMD (TXMD) Short-term Investments (2022)

TherapeuticsMD filings provide 1 years of Short-term Investments readings, the most recent being $11.2 million for Q4 2022.

On a quarterly basis, Short-term Investments changed N/A to $11.2 million in Q4 2022 year-over-year; TTM through Dec 2022 was $11.2 million, a N/A change, with the full-year FY2022 number at $11.2 million, changed N/A from a year prior.
Short-term Investments hit $11.2 million in Q4 2022 for TherapeuticsMD, roughly flat from $11.2 million in the prior quarter.
In the past five years, Short-term Investments ranged from a high of $11.2 million in Q2 2022 to a low of $11.2 million in Q2 2022.